.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Biosimilars Are Being Approved but Not Reaching the Market

July 17, 2019

Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA.

Just halfway through the year, 2019 has been busy for biosimilars, with new guidance and approvals but also the loss of a big advocate of biosimilars from the FDA. In this episode of Managed Care Cast, Kelly Davio, senior editor of The Center for Biosimilars^®, a sister site of The American Journal of Managed Care^®, discusses new approvals; what the loss of Scott Gottlieb, MD, as FDA commissioner means; the reality of pay-for-delay deals; and more.

Editor's note: since this conversation was recorded, 2 additional biosimilars, both anticancer agents, have launched in the United States. Learn more here.

Learn more about biosimilars at centerforbiosimilars.com.

Listen above or through one of these podcast services: